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Abstract 
A simple, sensitive and reproducible reverse-phase high performance liquid chromatographic (RP-
HPLC) method has been developed for the quantitative estimation of Atorvastatin calcium (ATOR-C) 
in the pharmaceutical formulations. Chromatographic separation was achieved on a 250 × 4.6 mm, 
5µ, Waters symmetry column. The flow rate was 1mL/min and eluent was monitored by absorbance 
at 246.0 nm using a mixture of Methanol and Acetonitrile (pH 3.0±0.01) in the ratio of 25:75 (v/v). 
The retention times of ATOR-C was found to be 5.5 min. Calibration plots were linear in the 
concentration range of 5-25 µg/mL for ATOR-C calcium. The total run time was 12 min. The 
proposed method was validated by testing its linearity, recovery, specificity, system suitability, 
precision (Interday, intraday, analyst and instrument precision), robustness and LOD/LOQ values and 
it was successfully employed for the determination of ATOR-C in pharmaceutical tablet formulations. 
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1.  Introduction: 
Atorvastatine Calcium (ATOR-C) (Figure 1) is 
the calcium salt (2:1) trihydrate of [R-(R*,R*)]-2-
(4-fluorophenyl)-b,d-dihydroxy-5-(1-
methylethyl)-3-phenyl4[(phenylamino) carbon 
yl] lH pyrrole-heptanoic acid. It is an inhibitor of 
3-hydroxy-3-methylglutaryl-coenzyme-A- 
(HMGCoA) reductase. ATOR-C is the most 
efficacious of the currently available HMG-CoA 
reductase inhibitors in terms of lowering plasma 
cholesterol levels by suppressing the hepatic 
production of very low density lipoprotein 
(VLDL) and low density lipoprotein (LDL) 
cholesterol1. 
A novel formulation ATOR-Ccommercially 
available, benefit for antihyperlipidemic action. 
This provides powerful efficacy for day long 
control of BP and has proven evidence in 
cardiovascular (CV) outcomes of ATOR-C2. 
Literature review revealed that there are various 
methods for determination of ATOR-Ccalcium, 
individually and in combination with other drugs. 
A variety of analytical methods are reported such 
as, estimation of enantiomeric of ATOR-C3, in 
human serum4 and its impurity in bulk drugs5. 
The majority of methods reported are liquid 
chromatography in which ATOR-Cwas estimated 
simultaneously with ezetimibe1, 6, 7, fenofibrate8, 
aspirin9, 10, ramipril11, 12, nicotinic acid13 and 
amLodipine 14, 15, 16, 17, 18. Some stability indicating 
RP-HPLC methods of ATOR-C and 
Amlodipine19 was also reported. Some triple 
combination of ATOR-C was reported with 
aspirin and pioglitazone20.  
The present manuscript describes a simple, rapid, 
precise and accurate isocratic Reversed‐phase 
HPLC method for determination of ATOR-C in 
the tablet dosage forms2. 
 
2. Experimental: 
a. Chemicals: ATOR-C (101.5%) was obtained 
from Cipla Pharmaceutical Ltd, Mumbai, India, 
as gift samples. Acetonitrile (HPLC Grade), 
Methanol (HPLC Grade), Potassium dihydrogen 
phosphate (AR Grade), ortho‐phosphoric acid 
(AR Grade) were purchased from E. Merck 
(India) Ltd. The 0.45‐µm nylon filters were 
purchased from Advanced Micro Devices Pvt. 
Ltd. Chandigarh, India. Mili‐Q water was used 
throughout the experiment. Tablets were 
purchased from Indian market containing of 
ATOR-C10.0 mg per tablet. 
b. Instruments: Analysis was performed on a 
chromatographic system Agilent 1200 series 
separation module (Japan) equipped with an auto 
injector (G1329A), Diode array detector SL 
(G1315C), Quaternary pump (G1311A) and 
column thermostat (G1316A). Data acquisition 
was made with Chemstation software. The peak 
purity was evaluated with DAD detector. 
c. Liquid chromatographic conditions: 
Chromatographic conditions were obtained using 
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a stainless steel column (Waters symmetry C18 
250mm x 4.6mm 5µm), which was maintained at 
40⁰C. The analytical wavelength was set at 246 
nm and samples of 20µl were injected to HPLC 
system. The mobile phase was Potassium 
dihydrogen phosphate (10mM, pH 3.0 adjusted 
with ortho‐phosphoric acid) and acetonitrile in 
ratio of 60:40 (v/v) at a flow rate of 1.0 mL/min. 
The mobile phase was filtered through 0.45µm 
filter and degassed for 10 minutes by sonication. 
d. Standard solutions:  
Stock standard solutions: An accurately 
weighed quantity of 10.0 mg of ATOR-C was 
transferred into a 100.0 mL volumetric flask. 
Dissolved with 25.0 mL of methanol and diluted 
to required volume with mobile phase, having the 
concentration of 100 µg/mL of ATOR-C.  
Preparation of working standard:From the 
standard stock solution 10.0 mL is pipette out 
into 100.0 mL volumetric flask and made up the 
volume with mobile phase, having the 
concentration of 10.0 µg/mL of ATOR-C. 
Preparation of laboratory mixture: Accurately 
weighed quantities of ATOR (≈10 mg) was 
transferred into a 100.0 mL volumetric flask, than 
dissolved with 25.0 mL of methanol and diluted 
to required volume with mobile phase, having the 
concentration of 100.0 µg/mL of ATOR. An 
accurately measured 1.0 mL portion of the 
resultant solution was diluted to 10.0 mL with 
diluent to obtain a laboratory mixture having 
concentration similar to marketed formulation. 
Sample preparation: Twenty tablets (ATOR, 
Dr. Reddy’s) were weighed and ground to a fine 
powder. An amount of powder equivalent to 
10.0mg of ATOR-C was weighed accurately and 
transferred into a 100.0 mL A‐grade volumetric 
flask containing 25.0 mL of methanol and 
sonicated for 30 min to effect complete 
dissolution of the ATOR-C and diluted upto 
100.0 mL with diluent, then the solution was 
filtered through 0.45 µm membrane filter and 
10.0 mL of filtrate taken into 100.0 mL 
volumetric flask. The aliquot portion of the 
filtrate was further diluted to get final 
concentration of 10.0 µg/mL of ATOR-C. 
e. Linearity study and Calibration curve: To 
study the linearity range of component, serial 
dilutions were made to obtained working 
standards in the concentration range of ATOR-C 
(5-25 µg/mL). A graph was plotted as 
concentration of drugs versus peak area response 
and results found linear for analytes. From the 
standard stock solution, a mixed standard of 
working concentration was prepared containing 
ATOR-C (10 µg/mL). The system suitability test 
was performed from five replicate injection of 
mixed standard solution. 
f. Analysis of Laboratory Mixture: In order to 
established suitability of the proposed method for 
quantative estimation of ATOR-C in the 
pharmaceutical formulations, the method was 
first tried for the estimation of the component in a 
standard laboratory mixture of two drugs by 
using equation 1 and 2.  
g. Analysis of Marketed Formulation: 20.0 µl 
of the standard and sample was injected 
separately and chromatograms are generated. 
With peak area obtained for standard and sample, 
the content of ATOR-C in each tablet was 
calculated using the following equation: 
 
Amount of drug present in each tablet =  
Sample area x Std. Conc. x Std. Purity x Avg. weight 
 Std. area x Sample conc.        
             ………………. (1) 
 
Percentage label claim   =  
                   Amount present    x 100 
                       Label claim ……………..………… (2) 
        
h. Recovery study:  Recovery studies were 
performed to validate the accuracy of developed 
method. For recovery study different 
concentrations (50%, 100% and 150%) of 
standard drug was prepared and then its recovery 
was analyzed. 
 i. Method validation: The HPLC method was 
validated in terms of precision, accuracy, 
specificity and linearity according to ICH 
guidelines22.  
Accuracy: The accuracy of the assay method was 
evaluated with the recovery of the standards from 
excipients. Three different quantities (low, 
medium and high i.e. 50%, 100% and 150%) of 
the authentic standards were added to the 
placebo. The mixtures were extracted as 
described in section 2d, and were analyzed using 
the developed HPLC method. 
Precision: Precision was determined using 
nine‐independent test solutions (3 concentration/3 
replicates). To study precision 80%, 100% and 
120% concentration was prepared and three 
replicate of each concentration was injected. The 
intermediate precision of the assay method was 
also evaluated using different analyst different 
days. 
Specificity: Accurately weighed quantities of the 
tablets powder equivalent to about 10 mg of 
ATOR was taken in a dry 50.0 mL volumetric 
flask. Each sample solution was stored under 
following different relevant small stress 
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conditions (light, heat, acid/base hydrolysis and 
oxidation) for sufficient time (24 hrs) to achieve 
10 to 30% degradation of the initial sample. 
1. Addition of small amount of alkali 
solution (0.1 N NaOH).  
2. Addition of small amount of acid 
solution (0.1 N HCl). 
3. Addition of small amount of oxidative 
agent (3% H2O2). 
4. Sample solution was heated 50 0C on 
water bath for a sufficient time 
5. Sample solution was exposed 600 foot-
candle of UV light for a sufficient time. 
 
After 24 hr each treated sample was analyzed and 
percent labeled claims were calculated by the 
method using formula under estimation of ATOR 
by proposed method. 
Linearity: Solutions for linearity study were 
prepared as described in Section 2e. Six 
replicates of each concentration were injected and 
results are examined and it was found that 
calibration curve was linear in the concentration 
range of 5-25 µg/mL for TELM with correlation 
coefficient (R2) 0.999.  
LOD and LOQ: The LOD and LOQ for analytes 
were estimated by SD of injecting a series of 
dilute solutions of known concentrations.  
Ruggedness: Ruggedness was ascertained by 
getting the sample analyzed from different 
analysts and carrying out analysis on different 
days by proposed method. 
Robustness: To determine the robustness of the 
method, the final experimental conditions were 
altered and the results were examined. The ratio 
of mobile phase was varied. 
 
3. Results and Discussion: 
Optimization of the chromatographic 
conditions: In order to develop RP‐HPLC 
method for antihyperlipidemic drug ATOR-Cin 
formulation. The chromatographic conditions 
were optimized for better resolution by using 
different buffers like phosphate, acetate and 
citrate for mobile phase preparation. After a 
series of screening experiments, it was concluded 
that Phosphate buffer (10mM Phosphate buffer 
pH at 3.0) gave better peak shapes than their 
acetate and citrate counterparts. With methanol as 
solvent both the peaks showed less theoretical 
plates and bad peak shapes, on changing to 
acetonitrile the peak shape improved along with 
theoretical plates. Further optimization 
experiments were carried out 30% and 40% of 
acetonitrile in mobile phase. The best peak shape 
and maximum separation was achieved with 
mobile phase composition consisting acetate 
buffer‐acetonitrile (60:40 v/v). The best 
separation, peak symmetry and reproducibility 
were obtained on Waters symmetry C18, 250 mm 
x 4.6 mm, 5 µm column compared to Hypersil 
ODS C18, 250 mm x 4.6 mm, 5 µm. The optimum 
wavelength for detecting the analytes was 
ascertained and found to be 246.0 nm.  
The specificity of the HPLC method is illustrated 
in Figure 2 and Figure 3, where complete 
separation of ATOR-C was noticed in presence of 
tablet excipients and its impurities produced by 
alkali and thermal degradation. There were no 
interfering peaks of endogenous compounds 
observed at the retention time of the analytes.  
Accuracy of the method was calculated by 
recovery studies at three levels by standard 
addition method (Table 1). The mean percentage 
recovery obtained for ATOR-C was 100.23. 
Precision is the degree of repeatability of an 
analytical method under normal operational 
conditions. The system precision is a measure of 
the method variability that can be expected for a 
given analyst performing the analysis and was 
determined by performing 80%, 100% and 120% 
analyses of the working solution.  
The intra‐day, inter‐day, analyst and instruments 
variability or precision data are summarized in 
Table 3.  The R.S.D of the assay results, 
expressed as percentage of the label claim, was 
used to evaluate the method precision. The 
inter‐day precision was also determined by 
assaying the tablets in triplicate per day. The 
results indicated the good precision of the 
developed method. 
The developed method was applied to the 
analysis of ATOR-C in tablet dosage from 
marketed as ATOCOR (Label claim 10 mg 
strength, Dr. Reddy’s). The results of analysis are 
given in Table 5 and Figure 4. The contents of 
marketed tablet dosage form were found to be in 
the range of 100±2% with RSD less than 2% 
which indicate suitability for routine analysis of 
ATOR-C in tablet dosage form. 
The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by 
small, but deliberate variations in method 
parameters and provides an indication of its 
reliability during normal usage. Robustness of the 
method was investigated under a variety of 
conditions including changes of pH of the mobile 
phase, flow rate, percentage of acetonitrile in the 
mobile phase. The mixed standard solution is 
injected in five replicates and sample solution of 
100% concentration is prepared and injected in 
triplicate for every condition and % R.S.D. of 
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assay was calculated for each condition. The 
degree of reproducibility of the results obtained 
as a result of small deliberate variations in the 
method parameters has proven that the method is 
robust (Table 4). 
 
Conclusion: 
A simple, specific, linear, precise and accurate 
RP‐HPLC method has been developed and 
validated for quantitative determination of 
ATOR-C in tablet formulation. The method is 
very rapid and specific as both peaks are well 
separated from its excipients peaks and with the 
total runtime of 12 min, makes the developed 
method it’s suitable for routine quality control of 
the selected drugs. 
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           Figure 1 Structure of ATOR-C  
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Figure 2 Alkali degradation test solution for specificity 
 
 
 
Figure 3 Thermal degradation test solution for specificity 
 
 
 
Figure 4 Test solution for assay 
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Table 1 Results of recovery analysis of ATOR-C 
 
Compound Wt. Spiked (%) Wt. recovered (%) Recovery (%) RSD (%) n=3 
Atorvastatin 50 50.60 101.2 0.008 
100 99.733 99.73 0.005 
150 149.663 99.77 0.004 
 
Table 2 System suitability Parameter of ATOR-C 
 
Parameters ATOR-C 
Theoretical plates 7425 
Peak Height 5.57
Peak Symmetry 0.935 
USP tailing 1.026 
Width at half height 0.640 
 
Table 3 Results of precision of ATOR-C 
 
Compound Precision Mean RSD (%) 
Atorvastatin Intra day 99.62 0.042 
Inter day 99.64 0.014 
Analyst 99.64 0.014 
Instrument 99.65 0.007 
 
Table 4 Results of robustness study of ATOR-C 
 
Factor Level Mean % assay (n=3) RSD (%) 
pH of mobile phase 3 99.6 0.209 
3.2 99.1 0.308 
Flow rate (mL/min) 1 99.5 0.058 
1.3 99.2 0.153 
% of Acetonitrile 30 99.2 0.209 
40 100.8 0.210 
 
Table 5 Quantitative analysis of marketed formulation of ATOR-C 
 
Tablet 
Sample 
Label Claim (mg) Amount present 
(mg/tablet) 
%Label Claim %Deviation 
Ator 10 10.15 100.99 +0.99 
 
